Waters (NYSE:WAT) Issues FY 2025 Earnings Guidance

Key Points

• Waters has issued FY 2025 earnings guidance with an expected EPS of 12.950-13.050 and revenue guidance of $3.1 billion-$3.2 billion, slightly above consensus estimates.
• The company's stock is experiencing a mix of analysts' ratings, with a consensus target price of $382.40 and varying opinions on its performance from different firms.
• Waters' stock is currently trading at $290.77 and is significantly influenced by institutional investors and hedge funds, which own 94.01% of the company's shares.

Waters (NYSE:WAT - Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided EPS guidance of 12.950-13.050 for the period, compared to the consensus EPS estimate of 12.923. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion. Waters also updated its Q3 2025 guidance to 3.150-3.250 EPS.

Waters Stock Performance

WAT opened at $290.77 on Monday. The company has a current ratio of 1.81, a quick ratio of 1.28 and a debt-to-equity ratio of 0.69. Waters has a 12-month low of $279.61 and a 12-month high of $423.56. The firm has a 50 day moving average of $332.57 and a two-hundred day moving average of $354.43. The firm has a market capitalization of $17.30 billion, a PE ratio of 26.39, a P/E/G ratio of 2.87 and a beta of 1.04.

Waters (NYSE:WAT - Get Free Report) last issued its earnings results on Monday, August 4th. The medical instruments supplier reported $2.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.92 by $0.03. Waters had a net margin of 22.02% and a return on equity of 41.70%. On average, analysts anticipate that Waters will post 12.86 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Barclays lowered their target price on Waters from $400.00 to $350.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. UBS Group restated a "neutral" rating on shares of Waters in a research report on Tuesday, July 15th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Waters in a report on Monday, July 14th. Scotiabank reissued a "sector outperform" rating and set a $465.00 price target on shares of Waters in a report on Friday, July 11th. Finally, Bank of America raised their price target on shares of Waters from $370.00 to $375.00 and gave the company a "neutral" rating in a research report on Thursday, June 26th. Ten equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $382.40.

Hedge Funds Weigh In On Waters

A number of hedge funds have recently made changes to their positions in WAT. Integrated Wealth Concepts LLC boosted its stake in shares of Waters by 2.9% in the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier's stock worth $386,000 after acquiring an additional 30 shares during the last quarter. Empowered Funds LLC raised its stake in Waters by 16.6% in the 1st quarter. Empowered Funds LLC now owns 1,126 shares of the medical instruments supplier's stock valued at $415,000 after purchasing an additional 160 shares during the last quarter. Brighton Jones LLC lifted its holdings in Waters by 112.9% in the 4th quarter. Brighton Jones LLC now owns 1,269 shares of the medical instruments supplier's stock valued at $471,000 after purchasing an additional 673 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Waters by 3.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 200,051 shares of the medical instruments supplier's stock worth $73,733,000 after purchasing an additional 6,976 shares during the last quarter. Institutional investors and hedge funds own 94.01% of the company's stock.

Waters Company Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.